Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vartan Garibyan

Cardiovascular Disease San Diego, CA Doctor of Osteopathy

NPI 1790084143 CMS profile 1382043

4060 4Th Ave Ste 500, San Diego, CA 92103

Open in the dashboard

General payments

$5,593

174 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vartan Garibyan of San Diego, CA is reported in the CMS Open Payments database as having received $5,593 across 174 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $523 24
2024 General $508 27
2023 General $732 37
2022 General $196 14
2021 General $391 21
2020 General $625 25
2019 General $2,618 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vartan Garibyan
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Vartan Garibyan were reported at $523. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Vartan Garibyan Cardiovascular Disease median Middle half National median
2019 $2,618 $450 $127–$1,392 $163
2020 $625 $242 $77–$751 $114
2021 $391 $335 $101–$1,037 $132
2022 $196 $395 $121–$1,211 $149
2023 $732 $443 $136–$1,283 $160
2024 $508 $450 $136–$1,323 $164
2025 $523 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $1,962 4 payments
  2. Novartis Pharmaceuticals Corporation $891 62 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $418 19 payments
  4. Amgen Inc. $346 15 payments
  5. Medtronic, Inc. $273 9 payments
  6. Medtronic Vascular, Inc. $221 6 payments
  7. Boston Scientific Corporation $194 8 payments
  8. Abbott Laboratories $156 7 payments
  9. Abiomed $139 1 payment
  10. AstraZeneca Pharmaceuticals LP $128 3 payments
  11. Other $865 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,801 171 payments
  2. Travel and Lodging $1,792 3 payments
Products named General payments · program years 2019–2025
  1. LEQVIO Cardiology/Vascular Diseases $418 30 payments
  2. LifeVest $418 19 payments
  3. ENTRESTO Cardiovascular $302 19 payments
  4. Repatha Cardiology $266 11 payments
  5. ENTRESTO Cardiology/Vascular Diseases $178 18 payments
  6. HeartWare HVAD $177 2 payments
  7. Impella $139 1 payment
  8. LEQVIO Cardiovascular $133 10 payments
  9. VIGILANT $116 5 payments
  10. REPATHA Cardiovascular $80 4 payments
  11. Other $1,610 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

3,470

Median for Cardiology: 2,533

Drug cost

$777,763

Median for Cardiology: $485,213

Branded share of claims

24.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 244 $308,613
Xarelto Rivaroxaban Brand 148 $150,174
Jardiance Empagliflozin Brand 107 $143,093
Entresto Sacubitril/Valsartan Brand 52 $82,126
Repatha Sureclick Evolocumab Brand 29 $31,974
Praluent Pen Alirocumab Brand 18 $21,747
Ezetimibe Generic 212 $4,397
Atorvastatin Calcium Generic 467 $3,808
Flecainide Acetate Generic 81 $3,556
Metoprolol Succinate Generic 216 $3,179

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$142,115

Medicare's payments for the services billed

Medicare patients

681

Average age 76

Services billed

2,549

302 women, 379 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 48%
Atrial fibrillation 45%
Heart failure 41%
Chronic kidney disease 35%
Diabetes 33%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $98
$98 — —
Repatha
  • Amgen Inc. $78
$78 29 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $49
$49 52 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $33
$33 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $25
$25 107 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

174 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record